Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 19;208(1):1-3.
doi: 10.1164/rccm.202304-0700ED. Online ahead of print.

Is Efficacy of Tezepelumab Independent of Severe Asthma Phenotype?

Guy Brusselle  1   2 , Sebastian Riemann  3
Affiliations

Is Efficacy of Tezepelumab Independent of Severe Asthma Phenotype?

Guy Brusselle et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Simplified scheme of postulated mechanisms by which tezepelumab might reduce asthma exacerbations: (1) reduced IL-5 driven eosinophilic inflammation, (2) decreased mucus production and mucus plugging, and (3) attenuated AHR. This illustration was created using BioRender.com. AHR = airway hyperresponsiveness; CYSLTR1 = cysteinyl leukotriene receptor 1; DC = dendritic cell; FcεRI = Fc epsilon receptor I; FeNO = fractional exhaled nitric oxide; ILC2 = type 2 innate lymphoid cell; iNOS = inducible nitric oxide synthase; MHC-II = major histocompatibility complex II; TCR = T cell receptor; Th2 = T-helper type 2; TSLP = thymic stromal lymphopoietin; TSLPR = thymic stromal lymphopoietin receptor.
See this image and copyright information in PMC

Comment on

  • doi: 10.1164/rccm.202210-2005OC

References

    1. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets . 2020;24:777–792. - PubMed
    1. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med . 2017;377:936–946. - PubMed
    1. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384:1800–1809. - PubMed
    1. Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR studies. Am J Respir Crit Care Med . 2023;208:13–24. - PMC - PubMed
    1. Humbert M, Albers FC, Bratton DJ, Yancey SW, Liu MC, Hozawa S, et al. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. Respir Med . 2019;154:69–75. - PubMed